Accessibility Menu
Humacyte logo

Humacyte

(NASDAQ) HUMA

Current Price$0.70
Market Cap$188.85M
Since IPO (2020)-93%
5 Year-93%
1 Year-68%
1 Month-33%

Humacyte Financials at a Glance

Market Cap

$188.85M

Revenue (TTM)

$2.02M

Net Income (TTM)

-$97.59M

EPS (TTM)

-$0.57

P/E Ratio

-1.22

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Price

$0.70

Volume

348,156

Open

$0.74

Previous Close

$0.70

Daily Range

$0.64 - $0.76

52-Week Range

$0.55 - $2.84

Estimated Earnings Date

Aug 10, 2026

HUMA News

HUMA: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Humacyte

Industry

Biotechnology

Employees

184

CEO

Laura E. Niklason, MD, PhD

Headquarters

Durham, NC 27713, US

HUMA Financials

Key Financial Metrics (TTM)

Gross Margin

-748.51%

Operating Margin

-5649.21%

Net Income Margin

-4840.82%

Return on Equity

-2781.56%

Return on Capital

-158.10%

Return on Assets

-88.27%

Earnings Yield

-81.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$188.85M

Shares Outstanding

269.64M

Volume

348.16K

Avg. Volume

8.03M

Financials (TTM)

Gross Profit

-$15.09M

Operating Income

-$113.89M

EBITDA

-$79.77M

Operating Cash Flow

-$101.54M

Capital Expenditure

-$831.00K

Free Cash Flow

-$102.38M

Cash & ST Invst.

$48.54M

Total Debt

$65.90M

Humacyte Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$495.00K

-4.3%

Gross Profit

-$1.54M

-5.5%

Gross Margin

-3.12%

N/A

Market Cap

$188.85M

N/A

Market Cap/Employee

$866.31K

N/A

Employees

218

N/A

Net Income

-$17.62M

-145.0%

EBITDA

-$13.56M

-130.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$48.54M

-22.8%

Total Debt

$65.90M

+315.8%

Accounts Receivable

$434.00K

-11.1%

Inventory

$9.92M

+23.7%

Long Term Debt

$63.47M

-18.1%

Short Term Debt

$2.43M

-19.2%

Return on Assets

-88.27%

N/A

Return on Invested Capital

-1.21%

N/A

Free Cash Flow

-$25.28M

+12.3%

Operating Cash Flow

-$25.10M

+12.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARCTArcturus Therapeutics Holdings Inc.
$7.01-0.99%
IMRXImmuneering Corporation
$4.60+1.32%
VYGRVoyager Therapeutics, Inc.
$3.68-0.54%
SGMTSagimet Biosciences Inc.
$6.93-1.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$7.86+0.26%
AALAmerican Airlines Group
$17.44+0.08%
NOKNokia
$13.81+0.01%
IBITiShares Bitcoin Trust
$33.87-0.04%

Questions About HUMA

What is the current price of Humacyte?

Humacyte is trading at $0.70 per share.

What is the 52-week range for Humacyte?

Over the past 52 weeks, Humacyte has traded between $0.55 and $2.84.

How much debt does Humacyte have?

As of the most recent reporting period, Humacyte reported total debt of $65.90M.

How much cash does Humacyte have on hand?

Humacyte reported $48.68M in cash and cash equivalents in its most recent financial results.

What is Humacyte’s dividend yield?

Humacyte does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.